Bay Pines VA Healthcare System
Bay Pines Researcher makes Alzheimer's related discovery
Alzheimer's is a tragic disease affecting millions of people and new effective and safe therapies are needed. According to the Alzheimer's Association *, it is the 6th leading cause of death in the United States and the 5th for those aged 65 and older. Bay Pines researchers studied the effects of cotinine in mice genetically altered for Alzheimer's like diseases. Cotinine is a compound derived from tobacco, but without the negative cardiovascular and addictive side effects. The researchers found that cotinine reduced brain plaques associated with dementia and prevented memory loss in the mice. Their findings have been published (online in advance of print) by the Journal of Alzheimer Disease *.
"We found a compound that protects neurons, prevents the progression of Alzheimer’s disease pathology, enhances memory and has been shown to be safe," said Valentina Echeverria, PhD, a scientist at Bay Pines VA Healthcare System and an assistant professor of Molecular Medicine at USF Health. "It looks like cotinine acts on several aspects of Alzheimer’s pathology in the mouse model. That, combined with the drug’s good safety profile in humans, makes it a very attractive potential therapy for Alzheimer’s disease."
While the current drugs for Alzheimer's may help delay the onset of symptoms, none halt or reverse the processes of Alzheimer's disease. In addition, existing drugs may have undesirable side effects.
Some epidemiological studies showed that people who smoke tend to have lower incidences of Parkinson's and Alzheimer's. Studies have widely attributed this apparently beneficial effect to nicotine, which has been reported to improve memory and reduce Alzheimer's-like plaques in mice. However, nicotine's harmful cardiovascular effects and addictive properties make the compound a less than ideal drug for neurodegenerative diseases.
The research team decided to look at the effects of cotinine, the major byproduct of nicotine metabolism, in Alzheimer's disease mice. Cotinine is nontoxic and longer lasting than nicotine. Furthermore, its safety has already been demonstrated in human trials evaluating cotinine's potential to relieve tobacco withdrawal symptoms.
The researchers administered cotinine daily for mice genetically altered to develop memory problems mimicking Alzheimer's disease as they aged. At the end of the five-month study, the Alzheimer's mice treated with cotinine performed better on tasks measuring their working memory and thinking skills than untreated Alzheimer's control mice. Long-term cotinine treatment appeared to provide the Alzheimer's mice complete protection from spatial memory impairment; their performance in this area of testing was identical to that of normal mice without dementia.
The brains of Alzheimer's mice treated with cotinine showed a 26-percent reduction in deposits of amyloid plaques, which are a hallmark of Alzheimer’s disease. Cotinine also inhibited the accumulation of the amyloid peptide oligomers – a predecessor of senile plaques – in the brains of these mice. Furthermore, the researchers discovered that cotinine stimulated the signaling factor Akt, which promotes the survival of neurons and enhances attention and memory.
Senile plaques likely had not yet formed or were just beginning to accumulate in the brains of the young adult mice when long-term cotinine treatment was started. The researchers suggest that "cotinine may be useful in preventing cognitive deterioration when administered to individuals not yet exhibiting Alzheimer’s disease cognitive impairment or those with mild cognitive impairment at early stages of the disease."
The researchers are seeking additional support for a pilot clinical trial to investigate cotinine's effectiveness in preventing progression to Alzheimer's dementia in patients with mild cognitive impairment, Echeverria said.
The VA-USF team is also studying the potential of the tobacco-derived compound to relieve fear-induced anxiety and help blunt traumatic memories in mouse models of post-traumatic stress disorder.
Study co-authors included researchers from the University of Miami, the University of Manchester (UK), Boston College, and Saitama Medical Center and Saitama Medical University (Japan). The study was supported in part by awards from the Florida Department of Health’s James and Esther King Biomedical Research Program, the Alzheimer’s Association and the Japan Society for the Promotion of Science.
Publication citation: "Cotinine Reduces Amyloid-β Aggregation and Improves Memory in Alzheimer’s Disease Mice," Valentina Echeverria, Ross Zeitlin, Sarah Burgess, Sagar Patel, Arghya Barman, Garima Thakur, Magorzota Mamcarz, Li Wang, David B. Sattelle, Daniel A. Kirschner, Takashi Mori, Roger M. LeBlanc, Rajeev Prabhakar and Gary W. Arendash, Journal of Alzheimer’s Disease, 24 (4) 2011. DOI: 10.3233/JAD-2011-102136, IOS Press.
VA Research and Development program: For more than 65 years, the Veterans Affairs (VA) Research and Development program has been improving veterans' lives through innovation and discovery. The VA Research program, unique in that it is the only research program focused wholly on conducting groundbreaking research to meet the full spectrum of veterans' medical needs, benefits from being part of the Veterans Health Administration (VHA) - an integrated, national health care system with a state-of-the-art electronic health record. Through dynamic combination, the VA Research program is able to promote the quick translation of research findings into advancements in health care for veterans and all Americans.
* Links will take you outside of the Department of Veterans Affairs website. VA does not endorse and is not responsible for the content of the linked websites. The link will open in a new window.